Anthony Altar,
Chief Science Officer and Sr. Vice President,
Assurex Health, Inc.
Dr. C. Anthony Altar, PhD, Chief Science Officer and Senior Vice President for Assurex Health, Inc., is responsible for the research and development of advanced technologies for psychiatric pharmacogenomic products. Before joining Assurex Health, Dr. Altar directed the Alzheimer’s Diagnostic Laboratory for the Blanchette Rockefeller Neuroscience Institute. Dr. Altar established The Biomarkers Consortium with the Foundation for NIH. His teams at Psychiatric Genomics Inc. discovered gene expression signatures of schizophrenia and validated drug targets for its control. As global director for neuroscience at Otsuka, Dr. Altar’s led the team that discovered Abilify and helped lead the Otsuka-BMS collaboration that resulted in its FDA approval. At Genentech and Regeneron Pharmaceuticals, Dr. Altar pioneered research of neurotrophic factors, and was the first to discover roles for BDNF in serotonin function and propose its role in the etiology and treatment of depression. Dr. Altar created digital imaging of receptor-drug binding in brain while a postdoctoral scientist UC Irvine, and identified the serotonin/dopamine receptor binding profile of atypical antipsychotics at Ciba-Geigy. Dr. Altar earned a BS with Honors in Psychobiology from UCLA and a Ph.D. with Honors in Psychology from UC Santa Barbara. He has published 135 neuroscience and drug discovery articles in peer-reviewed journals including Science and Nature.
GeneSight Psychotropic, a Combinatorial Pharmacogenomic Test, is Clinically Valid and Provides Clinical Utility for Patients with Treatment-resistant Depression
Monday, 27 October 2014 at 16:00
Add to Calendar ▼2014-10-27 16:00:002014-10-27 17:00:00Europe/LondonGeneSight Psychotropic, a Combinatorial Pharmacogenomic Test, is Clinically Valid and Provides Clinical Utility for Patients with Treatment-resistant DepressionSELECTBIOenquiries@selectbiosciences.com
Pharmacogenomics has been proposed to augment treatment response and decrease healthcare costs by optimizing therapeutic selection for patients. GeneSight Psychotropic is a combinatorial pharmacogenomic test that creates a composite phenotype based on allelic variations in 8 genes that encode CYP2D6, CYP2C19, CYP2C9, CYP1A2, CYP2B6, CYP3A4, the serotonin transporter, and the 5-HT2A receptor. The test stratifies 38 psychotropic medications into one of three cautionary categories, based on the metabolic pathways and mechanisms of action for each medication. Dr. Altar will review the genetic, genotypic, phenotypic, and combinatorial basis of the GeneSight test, and results of 3 prospective, 8-10 week long clinical studies involving 258 depressed subjects who had failed at least one antidepressant medication. Patients whose clinicians received the test had a 70% greater antidepressant response and more than twice the odds of response compared to unguided clinicians whose patients received the standard of care. The combinatorial pharamcogenomic apporach of the GeneSight test will also be shown for its superiority over single gene testing in predicting the clinical outcomes of unguided patients.
Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonCompanion DiagnosticsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2014-10-27 16:00:002014-10-27 17:00:00Europe/LondonGeneSight Psychotropic, a Combinatorial Pharmacogenomic Test, is Clinically Valid and Provides Clinical Utility for Patients with Treatment-resistant DepressionSELECTBIOenquiries@selectbiosciences.com
